Diammonium Glycyrrhizinate

Catalog No.S3622

For research use only.

Diammonium glycyrrhizinate (DG), a traditional Chinese medicine (TCM), is extracted and purified from liquorices (Radix glycyrrhizae). It is known for its anti-inflammatory effects, resistance to biologic oxidation and membranous protection. DG is able to reduce inflammatory injury via suppression of NF‑κB, TNF‑α and intercellular adhesion molecule 1.

Diammonium Glycyrrhizinate Chemical Structure

CAS No. 79165-06-3

Purity & Quality Control

Choose Selective Immunology & Inflammation related Inhibitors

Biological Activity

Description Diammonium glycyrrhizinate (DG), a traditional Chinese medicine (TCM), is extracted and purified from liquorices (Radix glycyrrhizae). It is known for its anti-inflammatory effects, resistance to biologic oxidation and membranous protection. DG is able to reduce inflammatory injury via suppression of NF‑κB, TNF‑α and intercellular adhesion molecule 1.
In vivo Intraperitoneal administration of DG protects mice against ConA-induced elevation of serum ALT levels and apoptosis of hepatocytes; at the same time, the absolute amount of hepatic NKT cells and T cells is significantly decreased, indicating that DG can inhibit the recruitment of lymphocytes into the liver. In addition, the production of IL-6 and IL-10 is improved by DG pretreatment, suggesting that DG may possibly protect the liver from injury via two pathways: direct protection of hepatocytes from apoptosis through an IL-6-dependent way and indirect inhibition of T-cell-mediated inflammation through an IL-10-dependent way[1]. DG is able to reduce inflammatory injury via suppression of nuclear factor κ‑light‑chain‑enhancer of activated B cells (NF‑κB), tumor necrosis factor‑α and intercellular adhesion molecule 1, which are thought to promote inflammatory injury. DG has neuroprotective potential against ischemia‑reperfusion injury in a model of focal cerebral ischemic‑reperfusion injury[2].

Protocol (from reference)

Animal Research:[2]
  • Animal Models: Sprague‑Dawley rats
  • Dosages: 10 mg/kg
  • Administration: i.p.
  • (Only for Reference)

Solubility (25°C)

In vitro

DMSO 100 mg/mL
(116.68 mM)
Water 100 mg/mL
(116.68 mM)
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 856.99
Formula

C42H62O16. 2H3N

CAS No. 79165-06-3
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC1(C2CCC3(C(C2(CCC1OC4C(C(C(C(O4)C(=O)O)O)O)OC5C(C(C(C(O5)C(=O)O)O)O)O)C)C(=O)C=C6C3(CCC7(C6CC(CC7)(C)C(=O)O)C)C)C)C.N.N

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04372914 Recruiting Dietary Supplement: BRB Lozenges Oral Cancer|Smoking|DNA Damage|Oxidative Stress Milton S. Hershey Medical Center|National Cancer Institute (NCI) October 7 2021 Not Applicable
NCT04643327 Recruiting Drug: Levetiracetam|Drug: Placebo Parkinson Disease|Mild Cognitive Impairment|Memory Impairment The University of Queensland|Queensland University of Technology|Johns Hopkins University|Cleveland Clinic Lou Ruvo Center for Brain Health|Royal Brisbane and Women''s Hospital February 9 2021 Phase 2
NCT04800874 Active not recruiting Drug: BBP-418 LGMD2I ML Bio Solutions Inc. February 18 2021 Phase 2
NCT01899833 Active not recruiting Diagnostic Test: 99mTc-Sestamibi Coronary Artery Disease Cell>Point LLC January 10 2021 Phase 2

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Diammonium Glycyrrhizinate | Diammonium Glycyrrhizinate supplier | purchase Diammonium Glycyrrhizinate | Diammonium Glycyrrhizinate cost | Diammonium Glycyrrhizinate manufacturer | order Diammonium Glycyrrhizinate | Diammonium Glycyrrhizinate distributor